PATENT CLAIM ANALYSIS

Application Number: 16002704
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["530", "324000"]

Abstract:
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th 2  immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.

Claim (Index 26):
The method of  claim 21 , wherein the fragment of the lipocalin mutein lacks at least one of the N-terminal and/or C-terminal amino acid compared to said lipocalin mutein.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 94.0
- Lexical Diversity: 1.56579
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14364449', '15367680', '12309820', '14981589', '13702792']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7388367735253286
- 35 USC 102 Novelty (BERT): 0.6038286189738779
- Combined Prediction Score: 0.7253359580701835
- Mean Citation Score: 497.254174
- Max Citation Score: 667.0369
- Similarity Product: 428.1381078046083

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test